RU2016111390A - Неконкурентные антагонисты никотиновых рецепторов - Google Patents
Неконкурентные антагонисты никотиновых рецепторов Download PDFInfo
- Publication number
- RU2016111390A RU2016111390A RU2016111390A RU2016111390A RU2016111390A RU 2016111390 A RU2016111390 A RU 2016111390A RU 2016111390 A RU2016111390 A RU 2016111390A RU 2016111390 A RU2016111390 A RU 2016111390A RU 2016111390 A RU2016111390 A RU 2016111390A
- Authority
- RU
- Russia
- Prior art keywords
- compound according
- alkyl
- disease
- condition
- oab
- Prior art date
Links
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 title 1
- 229960002715 nicotine Drugs 0.000 title 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 title 1
- 230000036963 noncompetitive effect Effects 0.000 title 1
- 239000002464 receptor antagonist Substances 0.000 title 1
- 229940044551 receptor antagonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010057852 Nicotine dependence Diseases 0.000 claims 3
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 claims 3
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 claims 3
- 208000025569 Tobacco Use disease Diseases 0.000 claims 3
- 208000024714 major depressive disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000001537 neural effect Effects 0.000 claims 3
- 230000005586 smoking cessation Effects 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/34—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton
- C07C211/38—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of a saturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
- C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
- C07D295/033—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to carbocyclic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (25)
1. Соединение формулы I:
Формула I,
где каждый из R1 и R2 в отдельности представляет собой H, C1-6алкил или арилзамещенный C1-6алкил, или R1 и R2 связаны с атом азота, к которому они присоединены, с образованием 3-8-членного кольца, необязательно замещенного C1-6алкильными, арильными, C1-6алкокси или арилокси заместителиями;
R3 представляет собой H, C1-6алкил или C1-6алкоксизамещенный C1-6алкил;
каждый из R4, R5, R6 и R7 в отдельности представляет собой H, C1-6алкил или C1-6алкоксигруппу;
L1 представляет собой линкер, выбранный из группы, состоящий из CR8R8, CR5R9CR10R11 и O;
L2 представляет собой линкер, выбранный из группы, состоящий из CH2, CH2CH2, CH2CH2CH2 или CH2CH2CH2CH2;
каждый из R8, R9, R10 и R11 в отдельности представляет собой водород или C1-6алкил, и
пунктирная линия обозначает необязательную двойную связь;
или его фармацевтически приемлемая соль.
2. Соединение по п.1, где R1 представляет собой H, и R2 представляет собой C1-6алкил.
3. Соединение по п.1 или 2, где R3 представляет собой C1-6алкил.
4. Соединение по п.1, где каждый из R4, R5, R6 и R7 представляет собой H.
5. Соединение по п.1, где L1 представляет собой CR8R9, и каждый из R8 и R9 представляет собой водород.
6. Соединение по п.1, где La представляет собой CH2CH2.
7. Соединение по п.1, где пунктирная линия обозначает одинарную связь.
8. Фармацевтическая композиция, содержащая соединение по любому из пп. 1-7 и фармацевтически приемлемый носитель.
9. Способ лечения или предотвращения заболевания или состояния, опосредованного нейрональным никотиновым рецептором, включающий введение соединения по любому из пп. 1-7.
10. Способ по п.9., где заболевание или состояние представляет собой IBS-D, OAB, никотиновую зависимость, прекращение курения, депрессию, большое депрессивное расстройство или гипертензию.
11. Применение соединения по любому из пп. 1-7 для получения лекарственного средства для лечения или предотвращения заболевания или состояния, опосредованного нейрональным никотиновым рецептором.
12. Применение по п.11, где заболевание или состояние представляет собой IBS-D, OAB, никотиновую зависимость, прекращение курения, депрессию, большое депрессивное расстройство или гипертензию.
13. Соединение по п.1, предназначенное для применения в качестве активного терапевтического вещества.
14. Соединение по п.1, предназначенное для применения в лечении или предотвращении заболевания или состояния, опосредованного нейрональным никотиновым рецептором.
15. Соединение по п.13 или 14, где заболевание или состояние представляет собой IBS-D, OAB, никотиновую зависимость, прекращение курения, депрессию, большое депрессивное расстройство или гипертензию.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34902710P | 2010-05-27 | 2010-05-27 | |
| US61/349,027 | 2010-05-27 | ||
| US37560610P | 2010-08-20 | 2010-08-20 | |
| US61/375,606 | 2010-08-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2016111390A true RU2016111390A (ru) | 2017-10-04 |
Family
ID=44462072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012157224/04A RU2582339C2 (ru) | 2010-05-27 | 2011-05-24 | Неконкурентные антагонисты никотиновых рецепторов |
| RU2016111390A RU2016111390A (ru) | 2010-05-27 | 2016-03-28 | Неконкурентные антагонисты никотиновых рецепторов |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012157224/04A RU2582339C2 (ru) | 2010-05-27 | 2011-05-24 | Неконкурентные антагонисты никотиновых рецепторов |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US8809397B2 (ru) |
| EP (1) | EP2576496B1 (ru) |
| JP (2) | JP5893610B2 (ru) |
| KR (1) | KR101856046B1 (ru) |
| CN (2) | CN104557568B (ru) |
| AU (1) | AU2011258553B2 (ru) |
| BR (1) | BR112012030004A2 (ru) |
| CA (1) | CA2799203C (ru) |
| CL (1) | CL2012003274A1 (ru) |
| CO (1) | CO6680603A2 (ru) |
| ES (1) | ES2623373T3 (ru) |
| IL (2) | IL223060A (ru) |
| MX (1) | MX337106B (ru) |
| NZ (1) | NZ603966A (ru) |
| PE (1) | PE20130775A1 (ru) |
| PH (1) | PH12012502300A1 (ru) |
| PL (1) | PL2576496T3 (ru) |
| RU (2) | RU2582339C2 (ru) |
| SG (1) | SG185643A1 (ru) |
| TW (1) | TW201200129A (ru) |
| UY (1) | UY33409A (ru) |
| WO (2) | WO2011149859A1 (ru) |
| ZA (1) | ZA201208836B (ru) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101856046B1 (ko) * | 2010-05-27 | 2018-06-25 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 니코틴 수용체 비-경쟁적 길항제 |
| JP2014532708A (ja) * | 2011-11-03 | 2014-12-08 | ターガセプト，インコーポレイテッド | ニコチン性受容体非競合的モジュレーター |
| WO2013142162A1 (en) * | 2012-03-23 | 2013-09-26 | Targacept, Inc. | Method of treating bladder disorders |
| US11840495B2 (en) | 2020-12-23 | 2023-12-12 | The Broad Institute, Inc. | Compositions and methods related to di-substituted bicyclo[2.2.1] heptanamine-containing compounds |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2931805A (en) * | 1958-11-10 | 1960-04-05 | Smith Kline French Lab | Spiro [bicyclo [2. 2. 1] heptane-2, 2'-alkylenimines] |
| US3290215A (en) * | 1963-10-29 | 1966-12-06 | Du Pont | Use of methanoindanamines as antiviral agents |
| US3317387A (en) * | 1964-05-25 | 1967-05-02 | Du Pont | Method of reducing the severity of influenza virus infections |
| IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
| US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
| US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
| US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
| JP2802486B2 (ja) | 1995-11-30 | 1998-09-24 | 花王株式会社 | トリシクロカルボン酸エステルおよびその製造法 |
| US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
| CN2284883Y (zh) | 1996-07-12 | 1998-06-24 | 陈智 | 纯滚活齿传动 |
| WO1998011882A1 (en) * | 1996-09-18 | 1998-03-26 | Codon Pharmaceuticals, Inc. | Pharmaceutical compositions and methods |
| ZA9711092B (en) | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US6310043B1 (en) | 1998-08-07 | 2001-10-30 | Governors Of The University Of Alberta | Treatment of bacterial infections |
| GB9821503D0 (en) | 1998-10-02 | 1998-11-25 | Novartis Ag | Organic compounds |
| ES2313187T3 (es) | 1998-12-16 | 2009-03-01 | University Of South Florida | Formulacion de exo-s-mecamilamina. |
| TW200306189A (en) * | 2002-03-21 | 2003-11-16 | Merz Pharma Gmbh & Co Kgaa | Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists |
| JP4511195B2 (ja) * | 2002-04-18 | 2010-07-28 | アストラゼネカ・アクチエボラーグ | フリル化合物 |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1663999A2 (en) * | 2003-08-29 | 2006-06-07 | Ranbaxy Laboratories, Ltd. | Inhibitors of phosphodiesterase type-iv |
| WO2005060947A2 (en) * | 2003-12-19 | 2005-07-07 | Sri International | Agonist and antagonist ligands of the nociceptin receptor |
| MXPA06007026A (es) * | 2003-12-22 | 2006-08-31 | Astrazeneca Ab | Ligandos del receptor nicotinico de acetilcolina. |
| UA92327C2 (ru) | 2004-08-20 | 2010-10-25 | Таргасепт, Инк. | Применение n-арилдиазаспироциклических соединений для лечения зависимостей |
| AR054816A1 (es) | 2005-07-13 | 2007-07-18 | Banyu Pharma Co Ltd | Derivados de n-dihidroxialquil 2-oxo- imidazol sustituidos |
| TW200845977A (en) * | 2007-03-30 | 2008-12-01 | Targacept Inc | Sub-type selective azabicycloalkane derivatives |
| WO2009039181A2 (en) | 2007-09-17 | 2009-03-26 | State Of Oregon Acting By & Through The State Board Of Higher Education On Behalf Of Or. State Univ. | Sulfonamide-based organocatalysts and method for their use |
| JP2011513421A (ja) | 2008-03-05 | 2011-04-28 | ターガセプト，インコーポレイテッド | サブタイプ選択的なジアザビシクロアルカンのアミド |
| KR101856046B1 (ko) * | 2010-05-27 | 2018-06-25 | 카탈리스트 바이오사이언시즈, 인코포레이티드 | 니코틴 수용체 비-경쟁적 길항제 |
| WO2013026852A2 (en) * | 2011-08-22 | 2013-02-28 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, Near Dublin | Derivatives of mecamylamine |
-
2011
- 2011-05-24 KR KR1020127033480A patent/KR101856046B1/ko not_active Expired - Fee Related
- 2011-05-24 PE PE2012002210A patent/PE20130775A1/es not_active Application Discontinuation
- 2011-05-24 NZ NZ603966A patent/NZ603966A/en not_active IP Right Cessation
- 2011-05-24 JP JP2013512132A patent/JP5893610B2/ja not_active Expired - Fee Related
- 2011-05-24 RU RU2012157224/04A patent/RU2582339C2/ru not_active IP Right Cessation
- 2011-05-24 MX MX2012013618A patent/MX337106B/es active IP Right Grant
- 2011-05-24 CN CN201510013360.XA patent/CN104557568B/zh not_active Expired - Fee Related
- 2011-05-24 PL PL11724498T patent/PL2576496T3/pl unknown
- 2011-05-24 AU AU2011258553A patent/AU2011258553B2/en not_active Ceased
- 2011-05-24 WO PCT/US2011/037630 patent/WO2011149859A1/en not_active Ceased
- 2011-05-24 EP EP11724498.8A patent/EP2576496B1/en not_active Not-in-force
- 2011-05-24 PH PH1/2012/502300A patent/PH12012502300A1/en unknown
- 2011-05-24 US US13/699,757 patent/US8809397B2/en not_active Expired - Fee Related
- 2011-05-24 BR BR112012030004A patent/BR112012030004A2/pt not_active IP Right Cessation
- 2011-05-24 ES ES11724498.8T patent/ES2623373T3/es active Active
- 2011-05-24 WO PCT/US2011/037634 patent/WO2011149862A1/en not_active Ceased
- 2011-05-24 CN CN201180026122.2A patent/CN102918021B/zh not_active Expired - Fee Related
- 2011-05-24 CA CA2799203A patent/CA2799203C/en not_active Expired - Fee Related
- 2011-05-24 SG SG2012084828A patent/SG185643A1/en unknown
- 2011-05-26 TW TW100118509A patent/TW201200129A/zh unknown
- 2011-05-26 UY UY0001033409A patent/UY33409A/es unknown
-
2012
- 2012-11-15 IL IL223060A patent/IL223060A/en active IP Right Grant
- 2012-11-22 ZA ZA2012/08836A patent/ZA201208836B/en unknown
- 2012-11-23 CL CL2012003274A patent/CL2012003274A1/es unknown
- 2012-12-21 CO CO12232450A patent/CO6680603A2/es active IP Right Grant
-
2014
- 2014-07-01 US US14/320,782 patent/US20140315877A1/en not_active Abandoned
-
2015
- 2015-08-27 US US14/837,023 patent/US9532974B2/en not_active Expired - Fee Related
- 2015-09-21 IL IL241743A patent/IL241743A0/en unknown
-
2016
- 2016-02-24 JP JP2016032562A patent/JP2016172717A/ja not_active Withdrawn
- 2016-03-28 RU RU2016111390A patent/RU2016111390A/ru not_active Application Discontinuation
- 2016-11-23 US US15/360,393 patent/US20170071878A1/en not_active Abandoned
-
2018
- 2018-01-23 US US15/877,725 patent/US10258582B2/en not_active Expired - Fee Related
-
2019
- 2019-04-15 US US16/383,880 patent/US10716770B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013512903A5 (ru) | ||
| CN109963854A (zh) | 杂芳基并[4,3-c]嘧啶-5-胺类衍生物、其制备方法及其在医药上的应用 | |
| JP2014500295A5 (ru) | ||
| JP2013526544A5 (ru) | ||
| JP2016503797A5 (ru) | ||
| JP2019517487A5 (ru) | ||
| JP2013509392A5 (ru) | ||
| JP2014521653A5 (ru) | ||
| JP2013533253A5 (ru) | ||
| JP2014506907A5 (ru) | ||
| JP2014511892A5 (ru) | ||
| RU2015143610A (ru) | Лечение катаплексии | |
| ATE517882T1 (de) | Chinolinderivate | |
| JP2017508782A5 (ru) | ||
| JP2014508804A5 (ru) | ||
| JP2014505107A5 (ru) | ||
| EA200901423A1 (ru) | Бензимидазолы и содержащие их фармацевтические композиции | |
| RU2015126015A (ru) | Новые улавливатели в лечении макулодистрофии | |
| RU2015120478A (ru) | Пери-карбинолы | |
| JP2016505637A5 (ru) | ||
| RU2017116196A (ru) | 2-амино-6-(дифторметил)-5,5-дифтор-6-фенил-3,4,5,6-тетрагидропиридины как ингибиторы васе1 | |
| JP2018527295A5 (ru) | ||
| JP2016513696A5 (ru) | ||
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| JP2013538213A5 (ru) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20190329 |